Electromed Earnings Call Highlights Growth and Buybacks

Electromed ((ELMD)) has held its Q2 earnings call. Read on for the main highlights of the call.

Electromed’s latest earnings call painted a broadly upbeat picture, with record revenue, stronger margins, and accelerating home-care momentum offsetting pockets of weakness in hospital and other revenue streams. Management stressed a large, underpenetrated market and a robust balance sheet, arguing that current investments and execution set up a durable growth runway.

Record Revenue and Growth Streak

Electromed reported Q2 FY2026 net revenue of $18.9 million, up 16.3% year over year and a new company record. This marks the thirteenth consecutive quarter of both revenue and profit growth, underscoring a consistent growth trajectory rather than a one-off spike.

Home Care Drives Core Performance

Direct home care revenue climbed 18.4% year over year to $17.3 million, reinforcing the home channel as the company’s key growth engine. Annualized home care revenue per weighted-average direct sales representative reached $1.2 million, above the $1.0–$1.1 million target range, with headcount averaging 58 reps and planned expansion to 61.

Profitability and Margins Move Higher

Gross profit rose to $14.8 million, representing 78.4% of net revenue versus 77.7% a year ago, reflecting continued margin expansion. Operating income jumped roughly 42.4% to $3.6 million, or 19.2% of sales, while net income increased 40.3% to $2.8 million and diluted EPS improved to $0.32 from $0.22.

Balance Sheet Remains a Key Asset

The company ended the quarter with $13.8 million in cash, no debt, working capital of $36.2 million, and shareholders’ equity of $45.4 million. Management highlighted this balance sheet strength as giving it flexibility to invest in growth while also returning capital to shareholders.

Shareholder Returns via Buybacks

Electromed’s board previously authorized a $10 million stock repurchase program, signaling confidence in the company’s valuation and outlook. In the six months ended December 31, 2025, the company deployed $3.8 million under this authorization, even as it continued to fund organic growth initiatives.

Commercial and Market Expansion Wins

The company executed 25 payer contracts in the first half of FY2026, adding roughly 2.9 million covered lives to an already large base exceeding 270 million. Its home care distributor channel also performed well, growing 12.1% year over year to about $900,000 and broadening the reach of its therapy.

Operational and Go-to-Market Enhancements

Electromed completed a manufacturing optimization that centers U.S.-based operations and assembly, a move aimed at efficiency and quality control. On the commercial side, it rolled out a CRM system and Smart Order e-prescribe platform, with over one-third of orders now electronic, and boosted education through trade shows, regional events, and virtual CEUs.

Large Untapped Market Opportunity

Management emphasized a sizable long-term runway, citing approximately 923,000 diagnosed bronchiectasis patients in the U.S., with only 16% currently using high-frequency chest wall oscillation therapy. Estimates of more than 4 million undiagnosed individuals further frame a substantial addressable market as awareness and diagnosis improve.

Hospital Channel Softness

Hospital revenue declined 9.4% year over year to about $700,000, a notable drag amid otherwise strong growth. Executives linked the weakness to prioritizing shipments for high-demand home patients and the inherently lumpy timing of hospital capital orders, while expressing confidence in eventual normalization.

Other Revenue and SG&A Trends

Other revenue fell 52.3% year over year to roughly $100,000, underscoring a contraction in non-core streams that have limited impact on the overall story. SG&A expenses rose 10% to $10.8 million, driven mainly by higher salaries and incentives tied to a larger sales force and elevated compensation, which management framed as growth investments.

Cash Use and Buyback-Driven Decline

Cash on hand declined by $1.5 million over the six months ended December 31, 2025, reversing a modest increase in the prior-year period. The decrease was primarily the result of $3.8 million in share repurchases, which more than offset $3.2 million of positive operating cash flow, indicating capital deployment rather than operational strain.

Under-Penetration and Education Gap

A registry analysis revealed that 58% of qualifying bronchiectasis patients were not prescribed HFCWO therapy despite meeting clinical criteria. Management framed this under-penetration as both a challenge and a major opportunity, underscoring the need for continued clinician education to drive higher adoption.

Monitoring Supply-Chain and Tariff Risk

While 99% of net revenue is generated in the U.S. and operations are largely domestic, Electromed acknowledged potential tariff exposure within upstream supplier networks. Management said it remains vigilant about these risks, indicating ongoing focus on supply-chain resilience and cost control.

Guidance and Forward-Looking Outlook

The company reiterated expectations for double-digit revenue growth and expanding operating leverage through the rest of FY2026, supported by a planned increase in direct reps to 61 and a home-care productivity target of $1.0–$1.1 million per rep. It aims to sustain gross margins in the mid-70% or better while leveraging Smart Order adoption, CRM-driven productivity, manufacturing gains, payer expansion, and a rebound in hospital demand.

Electromed’s earnings call showcased a company combining strong home-care-driven growth, rising profitability, and disciplined capital deployment with a clear focus on a large, underpenetrated respiratory market. Despite near-term softness in hospital and other revenues and higher SG&A, management’s confidence in its growth strategy and balance sheet strength appeared to resonate as the dominant theme.